Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO‐2 randomized clinical study

AIMS: Glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors treat type 2 diabetes through incretin‐signaling pathways. This study compared the efficacy and safety of the glucagon‐like peptide‐1 receptor agonist exenatide once‐weekly (Miglyol) suspension for autoinjection (Q...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadde, Kishore M., Vetter, Marion L., Iqbal, Nayyar, Hardy, Elise, Öhman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485171/
https://www.ncbi.nlm.nih.gov/pubmed/28205322
http://dx.doi.org/10.1111/dom.12908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485171/
https://www.ncbi.nlm.nih.gov/pubmed/28205322
http://dx.doi.org/10.1111/dom.12908

Ejemplares similares